GVS advice on liraglutide (Saxenda®) and naltrexon/ bupropion (Mysimba®) extension of further conditions

The National Health Care Institute has completed its assessment whether the List 2 conditions for liraglutide (Saxenda®) and naltrexone/ bupropion (Mysimba®) can be adjusted. Liraglutide (Saxenda®) and naltrexone/bupropion (Mysimba®) can be used for the treatment of adults with an extremely increased weight-related health risk. The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to add to the List 2 conditions that the treatment may only be prescribed if combined lifestyle intervention (CLI) is unsuccessful after one year.

Reason for request to adjust List 2 conditions

The request is based on the communications between the Ministry and the National Health Care Institute, to adjust the existing List 2 conditions for liraglutide (Saxenda®) and naltrexone/bupropion (Mysimba®). These communications have indicated a possible lack of clarity, in the practical field, about the List 2 conditions for these medicinal products, with regards to the appropriateness agreements already made by the occupational group. Adaptation of the List 2 conditions could possibly eliminate this ambiguity.

The National Health Care Institute's advice

We advise the Minister to adjust the List 2 condition for liraglutide and naltrexone/bupropion as follows in order to promote appropriate care (bold print):

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.